Related Experiment Videos
Anticonvulsant hypersensitivity reaction in pregnancy
Shad H Deering1, Kay Thompson, Janine Taylor
1Department of Obstetrics and Gynecology, National Naval Medical Center, Bethesda, Maryland, USA. deering95@hotmail.com
Obstetrics and Gynecology
|November 11, 2003
Summary
Anticonvulsant hypersensitivity reaction is a severe, potentially fatal condition linked to aromatic anticonvulsants. This case highlights the risk during pregnancy, emphasizing the need for vigilance in diagnosing this drug reaction.
Area of Science:
- Pharmacology
- Toxicology
- Obstetrics
Background:
- Anticonvulsant hypersensitivity reaction (AHS) is a severe, multisystemic adverse drug reaction.
- Aromatic anticonvulsants are common triggers for AHS, carrying a significant mortality risk.
- Pregnancy presents unique challenges for managing drug reactions due to potential risks to both mother and fetus.
Observation:
- A pregnant patient at 10 weeks' gestation developed AHS while on carbamazepine for a seizure disorder.
- Clinical manifestations included maculopapular rash, elevated liver enzymes, and pancytopenia.
- Discontinuation of the offending anticonvulsant led to complete resolution of symptoms.
Findings:
- The case demonstrates that AHS can occur during pregnancy.
- Prompt recognition and withdrawal of aromatic anticonvulsants are crucial for managing AHS.
- Successful management allowed for an uneventful pregnancy and delivery of a healthy infant.
Implications:
- Pregnant women using aromatic anticonvulsants are at risk for AHS.
- High clinical suspicion is essential for early diagnosis and management of AHS in pregnant patients.
- This case underscores the importance of careful medication monitoring during pregnancy.